New Data Confirms Low Risk of Severe Side Effects for Alzheimer’s Drug Lecanemab

Real-world evidence from WashU Medicine shows that lecanemab is safe for early-stage Alzheimer's patients under specialized care, with severe adverse events affecting only 1% of treated individuals.